SB206, is a topical antiviral gel for the treatment of viral skin infections. SB206 is currently being evaluated in B-SIMPLE4, a pivotal Phase 3 trial, for the treatment of treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipoxvirus.
B-SIMPLE4: Pivotal Phase 3 Study in Molluscum
For more information about the trial, please visit clinicaltrials.gov and reference identifier: NCT04535531.
Molluscum contagiosum is a common, contagious skin infection caused by the molluscipoxvirus. There are currently no FDA-approved therapies for molluscum, and, upon seeking treatment, caregivers are faced with potentially painful in-office, dermatologist-administered physical procedures or cantharidin, or recommended off-label prescriptions and over-the-counter products. More than half of the patients diagnosed with molluscum are untreated and over 30% of those treated receive an off-label prescription with no molluscum indication or proven clinical efficacy. The average time to resolution is 13 months, however, some children experience lesions that may not resolve in 24 months.